Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

1519 - Predicting Chemotherapy Toxicity in Elderly Patients with Advanced Non-small Cell Lung Cancer: A Prospective Multicenter Study of the National Hospital Organization in Japan

Date

28 Sep 2019

Session

Poster Display session 1

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Masaki Kanazu

Citation

Annals of Oncology (2019) 30 (suppl_5): v602-v660. 10.1093/annonc/mdz260

Authors

M. Kanazu1, M. Shimokawa2, R. Saito3, M. Mori1, A. Tamura4, Y. Okano5, Y. Fujita6, T. Endo7, M. Motegi8, S. Takata9, T. Kita10, N. Sukoh11, M. Takenoyama12, S. Atagi13

Author affiliations

  • 1 Department Of Thoracic Oncology, National Hospital Organization Osaka Toneyama Medical Center, 560-8552 - Toyonaka/JP
  • 2 Clinical Research Institute, National Hospital Organization National Kyushu Cancer Center, 811-1395 - Fukuoka/JP
  • 3 Division Of Respiratory Medicine, National Hospital Organization Shibukawa Medical Center, 377-0280 - Shibukawa/JP
  • 4 Department Of Respiratory Diseases, National Hospital Organization Tokyo National Hospital, 204-8585 - Kiyose/JP
  • 5 Division Of Pulmonary Medicine, National Hospital Organization Kochi National Hospital, 780-8077 - Kochi/JP
  • 6 Department Of Respiratory Medicine, National Hospital Organization Asahikiwa Medical Center, 070-8644 - Asahikawa/JP
  • 7 Department Of Respiratory Medicine, National Hospital Organization Mito Medical Center, 311-3193 - Mito/JP
  • 8 Department Of Respiratory Medicine, National Hospital Organization Takasaki General Medical Center, 370-0829 - Takasaki/JP
  • 9 Department Of Respiratory Medicine, National Hospital Organization Fukuoka-Higashi Medical Center, 811-3195 - Koga/JP
  • 10 Department Of Respiratory Medicine, National Hospital Organization Kanazawa Medical Center, 920-8650 - Kanazawa/JP
  • 11 Department Of Respiratory Medicine, National Hospital Organization Hokkaido Medical Center, 063-0005 - Sapporo/JP
  • 12 Department Of Thoracic Oncology, National Hospital Organization National Kyusyu Cancer Center, 811-1395 - Fukuoka/JP
  • 13 Department Of Thoracic Oncology, National Hospital Organization Kinki-Chuo Chest Medical Center, 5918555 - Sakai/JP

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1519

Background

Previous studies have developed risk stratification schemas to assess chemotherapy toxicity. However, it is controversial which geriatric assessment variables should be used to assess the individual risk of severe toxicity from chemotherapy in elderly patients.

Methods

Patients aged ≥70 years with advanced non-small cell lung cancer (NSCLC) treated at 24 National Hospital Organization institutions completed a pre-1st-line chemotherapy assessment, including the following: patient characteristics, treatment variables, laboratory test values, and geriatric assessment variables. Patients were followed through one cycle of chemotherapy to assess grade 3 (severe) to grade 5 (death) adverse events according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. We also analyzed clinical outcomes of all patients.

Results

In total, 348 advanced NSCLC patients with a median age of 76 years (range, 70 to 95 years) joined this prospective study. In all patients, the best objective response rate and disease control rate were 35.6% and 81.0%, respectively. Severe adverse events ≥grade 3 occurred in 136 patients (39.1%). Functional status (performance status, daily life independence level, and Barthel index; p = 0.0037, 0.0023, and 0.0214, respectively, between the ≥grade 3 cohort and the grade 0-2 cohort) and laboratory test results (anemia, albumin, and lactate dehydrogenase; p = 0.0497, 0.0171, and 0.0060 respectively, between the ≥grade 3 cohort and the grade 0-2 cohort) affected the occurrence of severe non-hematologic adverse events. For hematologic adverse events, body mass index, Charlson comorbidity, daily life independence level, recognition status, treatment variables, and anemia were involved with the occurrence of severe adverse events (p = 0.0488, 0.0333, 0.0358, 0.0276, < 0.0001, and 0.0271, respectively, between the ≥grade 3 cohort and the grade 0-2 cohort).

Conclusions

Geriatric assessment variables and several laboratory test values independently predicted vulnerability to chemotherapy in elderly patients with advanced NSCLC.

Clinical trial identification

UMIN000010384.

Editorial acknowledgement

Legal entity responsible for the study

The National Hospital Organization in Japan.

Funding

The National Hospital Organization in Japan.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.